US20200000745A1 - Chemical medicinal composition used for the improvement of sleep - Google Patents
Chemical medicinal composition used for the improvement of sleep Download PDFInfo
- Publication number
- US20200000745A1 US20200000745A1 US15/972,192 US201815972192A US2020000745A1 US 20200000745 A1 US20200000745 A1 US 20200000745A1 US 201815972192 A US201815972192 A US 201815972192A US 2020000745 A1 US2020000745 A1 US 2020000745A1
- Authority
- US
- United States
- Prior art keywords
- sleep
- medicinal composition
- improvement
- chemical
- composition used
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Definitions
- the chemical compound used for sleeplessness does not require a physicians prescription and is non-habit forming.
- a method for treating insomnia characterized by difficulties with sleep maintenance comprises administering a dosage of the chemical medicinal composition of C 30 H 38 CINO 3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep.
- the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C 30 H 38 CINO 3 or a pharmaceutically acceptable salt given prior to the start of sleep.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The compounds are of the class of antioxidant biogenic amines and a class of ethanolamines that are used to treat short-term insomnia by promoting sleep onset and maintenance.
Description
- A medicinal preparation to alleviate sleeplessness using the molecular formula;
-
C30H38CINO3 - The chemical compound used for sleeplessness does not require a physicians prescription and is non-habit forming.
- A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprises administering a dosage of the chemical medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep. the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt given prior to the start of sleep.
Claims (1)
1. A method for treating insomnia characterized by difficulties with sleep maintenance, wherein the method comprises administering a dosage of the chemical medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep. the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt given prior to the start of sleep.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/972,192 US20200000745A1 (en) | 2018-07-02 | 2018-07-02 | Chemical medicinal composition used for the improvement of sleep |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/972,192 US20200000745A1 (en) | 2018-07-02 | 2018-07-02 | Chemical medicinal composition used for the improvement of sleep |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200000745A1 true US20200000745A1 (en) | 2020-01-02 |
Family
ID=69054555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/972,192 Abandoned US20200000745A1 (en) | 2018-07-02 | 2018-07-02 | Chemical medicinal composition used for the improvement of sleep |
Country Status (1)
Country | Link |
---|---|
US (1) | US20200000745A1 (en) |
-
2018
- 2018-07-02 US US15/972,192 patent/US20200000745A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI3307271T3 (en) | Methods of using pyruvate kinase activators | |
HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
MXPA05012155A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases. | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
RU2017134443A (en) | METHOD OF TREATMENT WITH USE OF TRADIPTANT | |
RU2013148721A (en) | COMBINATIONS OF COMPOUNDS INHIBITING ACT AND VEMURAFENIBA AND WAYS OF THEIR APPLICATION | |
MX2021008247A (en) | Combination of dextromethorphan and bupropion for treating depression. | |
JP2018507243A5 (en) | ||
MX2010003556A (en) | Treatment regime for proliferative disorders. | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
MX2022015629A (en) | Use of vibegron to treat overactive bladder. | |
RU2012108656A (en) | APPLICATION OF 4-AMINOPYRIDINE TO IMPROVE CONDITION IN NEURO-COGNITIVE AND / OR NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH DEMILINIZING AND OTHER DISEASES OF THE NERVOUS SYSTEM | |
PE20221338A1 (en) | METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH FORMULATIONS OF LURBINECTEDIN | |
JP2016509050A5 (en) | ||
NZ751972A (en) | Treatment of prurigo nodularis | |
ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
MX2013003523A (en) | Low dose pharmaceutical composition comprising zanamivir. | |
MX2022006083A (en) | Methods of treating conditions related to the s1p1 receptor. | |
BRPI0508983A (en) | use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt and a taxane, pharmaceutical composition, kit, and method for producing antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal such as as a human being | |
MX2021008986A (en) | Methods of treating a patient having parkinson's disease. | |
US20200000745A1 (en) | Chemical medicinal composition used for the improvement of sleep | |
CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
MX2010006310A (en) | O-desmethyl-venlafaxine for treating major depressive disorder. | |
MX2021007324A (en) | Oral therapy using 6,8-bis-benzylthio-octanoic acid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |